Search Results
Sep 04, 2025, 12:15 ET TECNO Unveils Latest TECNO Slim and AIoT Ecosystem, Expands Laptop Business Reach in Spain and France
consumers, dramatically expanding TECNO's market influence in this important European region. TECNO has successfully established its partnership with MCR, Spain's largest technology distributor in early June, and is now available in the Spanish market through both online
More news about: TECNO
Sep 03, 2025, 10:57 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHCO and WOW on Behalf of Shareholders
Soho House & Co Inc. (NYSE: SHCO)'s sale to affiliates of MCR for $9.00 per share in cash. If you are a Soho shareholder,
More news about: Halper Sadeh LLP
Sep 02, 2025, 08:01 ET BUYOUT INVESTIGATION NOTICE: Kaskela Law LLC Announces Investigation of Soho House & Co Inc. (NYSE: SHCO) Stockholder Buyout and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options
https://kaskelalaw.com/case/soho-house/ On August 18, 2025, Soho House announced that it had agreed to be acquired by an investment group led by MCR and Soho House's Executive Chairman at just $9.00 per share in cash. Our Firm's investigation so far has discovered
More news about: Kaskela Law LLC
Aug 28, 2025, 12:48 ET Safety Gloves Market to Reach USD 30,358.87 Million by 2032, growing at a CAGR of 7.20%: Credence Research
3MANSELL LTD.Top Glove CorporationKossan Rubber IndustriesDeltaPlus GroupMCR SafetyErgodyneSaf-T-Gard International, IncRadians IncProtective Industrial Products, IncRecent Industry
More news about: Credence Research Inc.
Aug 26, 2025, 13:10 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DAY, WOW, VRNT, SHCO on Behalf of Shareholders
click here to learn more about your legal rights and options. Soho House & Co Inc. (NYSE: SHCO)'s sale to affiliates of MCR for $9.00 per share in cash. If you are a Soho shareholder,
More news about: Halper Sadeh LLP
Aug 21, 2025, 13:15 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GES, SHCO, OLO on Behalf of Shareholders
click here to learn more about your legal rights and options. Soho House & Co Inc. (NYSE: SHCO)'s sale to affiliates of MCR for $9.00 per share in cash. If you are a Soho shareholder,
More news about: Halper Sadeh LLP
Aug 19, 2025, 18:27 ET SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Soho House & Co Inc. (NYSE: SHCO)
SHCO) related to its merger with affiliates of MCR Hotels. Under the terms of the proposed transaction, Workhorse shareholders will receive $9.00 per share in cash. Is
More news about: Monteverde & Associates PC
Aug 18, 2025, 12:00 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHCO and WKHS on Behalf of Shareholders
Soho House & Co Inc. (NYSE: SHCO)'s sale to affiliates of MCR for $9.00 per share in cash. If you are a Soho shareholder,
More news about: Halper Sadeh LLP
Jul 31, 2025, 06:00 ET The Cigna Group Reports Strong Second Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook
income from operations, pre-tax1, decreased 9% relative to second quarter 2024, primarily driven by a higher MCR4.The Cigna Healthcare MCR4 was 83.2% for second quarter 2025 compared to 82.3% for second quarter 2024, primarily due to expected higher stop loss
More news about: The Cigna Group
Jul 23, 2025, 17:31 ET Claudin 18.2-Directed Oncology Therapeutics--A Fast-Growing Market with Blockbuster Potential | DelveInsight
others, are currently engaged in the development and production of CLDN 18.2 therapies, which have the potential to significantly impact and enhance the MCR therapies market. ASKB589 is a humanized IgG1 monoclonal antibody targeting CLDN1, specifically designed to enhance antibody-dependent
More news about: DelveInsight Business Research, LLP
Jul 15, 2025, 07:30 ET Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity
obesity, representing a significant unmet medical need. About Melanocortin Receptor AgonistsThe melanocortin receptor ("MCR") system has effects on inflammation, immune system responses, metabolism, food intake, and sexual function. There are five melanocortin receptors, MC1R
More news about: Palatin Technologies, Inc.
Jul 14, 2025, 17:31 ET MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight
others.Leading MCR therapy companies, such as Palatin Technologies, Rhythm Pharmaceuticals, Crinetics Pharmaceuticals, and others, are developing novel MCR therapies that can be available in the MCR therapies market in the coming years. Some of the key MCR therapies in the pipeline
More news about: DelveInsight Business Research, LLP
Jun 15, 2025, 03:42 ET MCR Oil Tools объявляет о подтверждении Администрацией по безопасности трубопроводов и опасных материалов статуса невзрывоопасных, невзрывоопасных материалов для отгрузки своих термитных инструментов
совокупности увеличивают затраты для MCR и нефтегазовой промышленности в целом. Разрешение PHMSA для MCR на отгрузку своих RCT в качестве невзрывоопасных и безопасных признает действительно безопасный характер технологии MCR и упрощает непрерывное распределение резаков MCR среди производителей нефти и
More news about: MCR Oil Tools LLC
Jun 15, 2025, 03:39 ET MCR Oil Tools zverejňuje potvrdenie od PHMSA o nehorľavosti a bezpečnosti svojich zásielok termitového náradia
spoločnosť MCR na prepravu jej RCT ako nevýbušných a bezpečných potvrdzuje skutočne bezpečnú povahu technológie MCR a zjednodušuje ďalšiu distribúciu horákov MCR producentom ropy a plynu, ako aj servisným firmám po celom svete. Mike Robertson, zakladateľ a generálny riaditeľ spoločnosti MCR Oil Tools,
More news about: MCR Oil Tools LLC
Jun 13, 2025, 12:09 ET Společnost MCR Oil Tools oznamuje, že PHMSA potvrdila pro účely přepravy, že její termitové nářadí je nehořlavé a že nepředstavuje nebezpečný materiál
pro společnost MCR dodávat své hořáky RCT jako nevýbušné a nikoli nebezpečné zohledňuje bezpečnou povahu technologie společnosti MCR a zjednodušuje jejich další distribuci výrobcům ropy a plynu a servisním firmám po celém světě. Mike Robertson, zakladatel a výkonný ředitel společnosti MCR Oil Tools, uvedl:
More news about: MCR Oil Tools LLC
Jun 13, 2025, 12:05 ET MCR Oil Tools ogłasza, że PHMSA przyznała transportowi narzędzi z materiałów termitowych status przewozu materiałów niewybuchowych i innych niż niebezpieczne
co zwiększa koszty dla MCR i generalnie dla przemysłu naftowego i gazowego. Zezwolenie PHMSA dla MCR na transport RCT jako materiałów niewybuchowych i innych niż niebezpieczne stanowi uznanie dla bezpieczeństwa technologii MCR i upraszcza dalszą dystrybucję palników MCR do producentów ropy i gazu
More news about: MCR Oil Tools LLC
Jun 13, 2025, 12:00 ET MCR Oil Tools anuncia que el envío de sus herramientas Thermite es seguro
los costes para MCR y la industria del petróleo y el gas en general. La autorización de PHMSA para que MCR envíe sus RCT como no explosivos ni peligrosos reconoce la verdadera seguridad de la tecnología de MCR y simplifica la distribución continua de las antorchas MCR a productores
More news about: MCR Oil Tools LLC
Jun 12, 2025, 20:57 ET MCR Oil Tools annonce la confirmation par la PHMSA du statut non explosif et non Hazmat pour l'expédition de ses Thermite Tools
augmentation des coûts pour MCR et, plus généralement, pour l'industrie pétrolière et gazière. L'autorisation donnée par la PHMSA à MCR d'expédier ses RCTs en tant que produits non explosifs et non dangereux reconnaît la nature véritablement sûre de la technologie de MCR et simplifie la distribution
More news about: MCR Oil Tools LLC
Jun 12, 2025, 20:53 ET MCR Oil Tools gibt die Bestätigung der PHMSA bekannt, dass der Versand seiner Thermite Tools nicht explosiv und nicht gefährlich ist
Kosten für MCR und die Öl- und Gasindustrie im Allgemeinen in die Höhe treibt. Die Genehmigung der PHMSA für MCR, seine RCTs als nicht explosiv und nicht gefährlich zu versenden, erkennt die wirklich sichere Natur der Technologie von MCR an und vereinfacht den weiteren Vertrieb von MCR Torches an
More news about: MCR Oil Tools LLC
Jun 12, 2025, 12:42 ET MCR Oil Tools Announces PHMSA Confirmation of Non-Explosive, Non-Hazmat Status For Shipment Of Its Thermite Tools
which combine to increase costs for MCR and the oil and gas industry more broadly. PHMSA's authorization for MCR to ship its RCTs as non-explosive and non-hazardous recognizes the truly safe nature of MCR's technology and simplifies the continued distribution of MCR Torches to oil and gas producers
More news about: MCR Oil Tools LLC
Jun 12, 2025, 12:34 ET MCR Oil Tools Announces PHMSA Confirmation of Non-Explosive, Non-Hazmat Status For Shipment Of Its Thermite Tools
which combine to increase costs for MCR and the oil and gas industry more broadly. PHMSA's authorization for MCR to ship its RCTs as non-explosive and non-hazardous recognizes the truly safe nature of MCR's technology and simplifies the continued distribution of MCR Torches to oil and gas producers
More news about: MCR Oil Tools LLC
Jun 05, 2025, 03:00 ET TECNO se asocia con MCR para llevar su innovador ecosistema de productos AIoT a España
innovadora impulsada por IA, ha anunciado una asociación estratégica con MCR, el principal mayorista tecnológico de España, para llevar su competitivo y galardonado ecosistema de productos AIoT a los mercados español y europeo. Juntos, TECNO y MCR tienen como objetivo ofrecer a los consumidores una experiencia
More news about: TECNO
Jun 02, 2025, 21:25 ET 亞盛醫藥Bcl-2抑制劑Lisaftoclax針對維奈克拉治療失敗患者口頭報告數據強勁，全球競爭優勢明顯|直擊2025 ASCO
的患者獲MLFS。- 在15例療效可評估的 ND MDS/慢性粒單核細胞白血病（CMML）患者中，ORR為 80%，其中40%的患者獲CR，40%的患者獲骨髓CR（mCR）。22 例療效可評估的 R/R MDS/CMML 患者中，ORR為 50%，其中27.3%的患者獲 CR，18.2%的患者獲 mCR，4.5%的患者獲PR。安全性數據：Lisaftoclax聯合AZA治療，耐受性良好，安全性可控，常見不良反應主要體現在血液學事件，非血液學毒性不常見。絕大多數不良事件都可控制、可恢復、可耐受。 總結： Lisaftoclax聯合AZA治療TN或復發/難治髓系惡性腫瘤患者，展現出出色的臨床療效以及安全性。特別是，lisaftoclax展示出克服維奈克拉耐藥的潛力，是國際上首次報告新型Bcl-2抑制劑克服維奈克拉耐藥的臨床研究。
More news about: 亞盛醫藥
May 14, 2025, 07:30 ET Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
$9.2 million, for the comparable quarter last year. The decrease was mainly the result of the decrease in spending related to our MCR programs for the third quarter ended March 31, 2025. Other (Expense) / Income Total
More news about: Palatin Technologies, Inc.
May 09, 2025, 07:30 ET Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
globally.About Melanocortin Receptor SystemThe melanocortin receptor (MCR) system plays a critical role in regulating inflammation, immune response, and tissue repair. MCR agonists have shown promise in restoring tissue homeostasis in ocular, gastrointestinal, and renal
More news about: Palatin Technologies, Inc.